margot.beereboom@fwo.be
+32 2 550 15 76
Marie Sklodowska-Curie Fellowships are European research grants available to researchers regardless of their nationality or field of research. In addition to generous research funding scientists have the possibility to gain experience abroad and in the private sector, and to complete their training with competences or disciplines useful for their careers.
The Marie Sklodowska-Curie programme aims to foster innovation, research-business cooperation and also includes a strong international component based on the principle of mobility.
The MSCA provides funding for all stages of research careers, being doctoral candidates or highly experienced researchers and by ensuring good working conditions and work/life balance for the researchers.
The programme is open to all fields of research and innovation, from fundamental research to market take-up and innovation services. Furthermore, it also encourages mobility between the different sectors (universities, research centres, and companies), disciplines and countries.
There are five types of Marie Sklodowska-Curie Actions:
Infosheets contain edited content on aspects related to this programme. They are reviewed at least yearly.
Related links are easy pointers towards external information. We curate the list, but are not liable for the destinations.
Documents contain additional information related to this programme, and are similar to related links.
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.